Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 8, 2015, Pages 1418-1424

  Vaughn, Jennifer E ^a,b   Storer, Barry E ^a,c   Armand, Philippe ^d   Raimondi, Roberto ^e   Gibson, Christopher ^d   Rambaldi, Alessandro ^f   Ciceri, Fabio ^g   Oneto, Rosi ^h   Bruno, Benedetto ⁱ   Martin, Paul J ^a,b   Sandmaier, Brenda M ^a,b   Storb, Rainer ^a,b   Sorror, Mohamed L ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e SAN BORTOLO HOSPITAL   (Italy)

^f Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

Author keywords

Albumin; Biomarkers; Ferritin; HCT CI; HCT comorbidity index; Hematopoietic cell transplantation; Platelet count survival

Indexed keywords

ALBUMIN; FERRITIN; HEMOGLOBIN D; ALBUMINOID;

ADULT; ALBUMIN BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASSESSMENT OF HUMANS; FERRITIN BLOOD LEVEL; GRAFT RECIPIENT; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HEMOGLOBIN BLOOD LEVEL; HUMAN; ITALY; LABORATORY TEST; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; THROMBOCYTE COUNT; TRAINING; UNITED STATES; VALIDATION STUDY; ALLOTRANSPLANTATION; COMORBIDITY; DEVICES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

ALBUMINS; COMORBIDITY; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VALIDATION STUDIES AS TOPIC;

EID: 84937730075     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.04.002     Document Type: Article

References (42)

1. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
2. Raimondi R., Tosetto A., Oneto R., et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood 2012, 120:1327-1333.
3. Sorror M.L., Logan B.R., Zhu X., et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index (HCT-CI) for HCT outcomes at US transplant centers: a Center for International Blood and Marrow Transplant Research (CIBMTR) study. Blood 2012, 120. abstr 733.
4. Elsawy M, Storer BE, Pulsipher MA, etal. Multi-center validation of the prognostic value of the hematopoieitc cell transplantation-specific comorbidity index among recipients of allogeneic hematopoietic cell transplantation. Br J Haematol (in press).
5. Sorror M.L., Estey E. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. Hematology 2014, 2014:21-33.
6. Elsawy M, Sorror ML. Assessment of comorbidities: achievements and controversies. In: Lazarus H, Abutalib S, editors. Hematopoietic transplantation: bone marrow, blood and cell therapies. Cambridge University Press (in press).
7. Sorror M.L., Maris M.B., Storb R.F., et al. Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biol Blood Marrow Transplant 2005, 11(Suppl 1):23-24.
8. Goldwasser P., Feldman J. Association of serum albumin and mortality risk. JClin Epidemiol 1997, 50:693-703.
9. Knaus W.A., Wagner D.P., Draper E.A., et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991, 100:1619-1636.
10. Durken M., Herrnring C., Finckh B., et al. Impaired plasma antioxidative defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med 2000, 28:887-894.
11. Evens A.M., Mehta J., Gordon L.I. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 2004, 34:561-571.
12. Kataoka K., Nannya Y., Hangaishi A., et al. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:195-204.
13. Kanda J., Mizumoto C., Ichinohe T., et al. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2011, 46:208-216.
14. Scott B.L., Park J.Y., Storer B., et al. Impact of pretransplant neutropenia on post-transplant outcome in patients with myelodysplastic syndrome (MDS). Blood 2006, 108(Pt 1). abstr 599.
15. Deeg H.J., Scott B.L., Fang M., et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012, 120:1398-1408.
16. Walter R.B., Kantarjian H.M., Huang X., et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center study. JClin Oncol 2010, 28:1766-1771.
17. Bacigalupo A., Ballen K., Rizzo D., et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009, 15:1628-1633.
18. Mahindra A., Bolwell B., Sobecks R., et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 2009, 146:310-316.
19. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007, 109:4586-4588.
20. Armand P., Kim H.T., Rhodes J., et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:852-860.
21. Rezvani A.R., Storer B.E., Storb R.F., et al. Decreased serum albumin as a biomarker for severe acute graft-vs-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1594-1601.
22. Kharfan-Dabaja M.A., Chavez J.C., Yu D., et al. Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2011, 17:384-393.
23. Harrell F.E., Lee K.L., Califf R.M., et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984, 3:143-152.
24. Mahindra A., Sobecks R., Rybicki L., et al. Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation. Bone Marrow Transplant 2009, 44:767-768.
25. Sivgin S., Baldane S., Kaynar L., et al. Pretransplant serum ferritin level may be a predictive marker for outcomes in patients having undergone allogeneic hematopoietic stem cell transplantation. Neoplasma 2012, 59:183-190.
26. Lim Z.Y., Fiaccadori V., Gandhi S., et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk Res 2010, 34:723-727.
27. Pullarkat V., Blanchard S., Tegtmeier B., et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2008, 42:799-805.
28. Scott B.L., Park J.Y., Deeg H.J., et al. Pre-transplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. Biol Blood Marrow Transplant 2008, 14:799-806.
29. Armand P., Sainvil M.M., Kim H.T., et al. Does iron overload really matter in stem cell transplantation?. Am J Hematol 2012, 87:569-572.
30. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010, 95:476-484.
31. Sivgin S., Baldane S., Ozenmis T., et al. The impact of pretransplant hypoalbuminemia on survival in patients with leukemia who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT): a nutritional problem?. Transplant Proc 2013, 45:3371-3374.
32. Pullarkat V., Blanchard S., Tegtmeier B., et al. Iron overload adversely affects survival and increases risk of graft-versus-host disease and blood stream infections after allogeneic hematopoietic stem cell transplantation. Blood 2007, 110(Pt 1):875a-876a.
33. Trottier B.J., Burns L.J., Defor T.E., et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood 2013, 122:1678-1684.
34. Wermke M., Schmidt A., Middeke J.M., et al. MRI-based liver iron content predicts for nonrelapse mortality in MDS and AML patients undergoing allogeneic stem cell transplantation. Clin Cancer Res 2012, 18:6460-6468.
35. Virtanen J.M., Itala-Remes M.A., Remes K.J., et al. Prognostic impact of pretransplant iron overload measured with magnetic resonance imaging on severe infections in allogeneic stem cell transplantation. Eur J Haematol 2013, 91:85-93.
36. Naoum F.A., Espósito B.P., Ruiz L.P., et al. Assessment of labile plasma iron in patients who undergo hematopoietic stem cell transplantation. Acta Haematol 2013, 131:222-226.
37. Sivgin S., Baldane S., Akyol G., et al. The oral iron chelator deferasirox might improve survival in allogeneic hematopoietic cell transplant (alloHSCT) recipients with transfusional iron overload. Transfus Apher Sci 2013, 49:295-301.
38. Armand P., Sainvil M.M., Kim H.T., et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant 2013, 48:146-147.
39. Hoffmeister P.A., Storer B.E., Macris P.C., et al. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2013, 19:1081-1086.
40. Farias C.L., Campos D.J., Bonfin C.M., Vilela R.M. Phase angle from BIA as a prognostic and nutritional status tool for children and adolescents undergoing hematopoietic stem cell transplantation. Clin Nutr 2013, 32:420-425.
41. Deeg H.J., Seidel K., Bruemmer B., et al. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant 1995, 15:461-468.
42. Sorror M. How I assess comorbidities prior to hematopoietic cell transplantation. Blood 2013, 121:2854-2863.